High-risk patients (age >45, male gender, presence of metastatic disease, extra-thyroidal tumour extension, and tumour diameter >4 cm) should also receive thyroid stimulating hormone (TSH) suppression therapy with thyroid hormone [8]. Here, TG is linked to neoplasm.